Researchers have said psychedelic-assisted psychotherapy may hold promise for both improving health and saving costs, but that the current therapeutic approach is poorly targeted.
Research and drug development company Albert Labs has announced it will begin trading on the CSE.
Vancouver-based Apex Labs has received approval for a Phase IIa clinical trial exploring psilocybin treatment for post-traumatic stress disorder (PTSD) in veterans.
One company is hoping to combine the altered state of the psychedelic experience with the unreal environment of virtual reality (VR) to improve anxiety.
Field Trip Health is partnering with online mental health platform, Cerebral, to provide improved mental health care.
Psychedelic-assisted psychotherapy is being investigated by Novamind to help people with difficult-to-treat indications and who are historically underserved.
New results have demonstrated treating major depressive disorder (MDD) with psilocybin-assisted psychotherapy is effective for up to a year in some patients.
The philanthropic arm of atai Life Sciences, atai Impact, has donated $500,000 to The Multidisciplinary Association for Psychedelics (MAPS) for multi-year support of MAPS’ ongoing initiatives,...
Some patients hospitalised with severe suicidal thoughts could benefit from ketamine treatment.
The thematic ETF will track the performance of the Enhanced Consciousness Index – comprised of companies involved in the legal research, development and production of psychedelics...